spacer
home > ict > autumn 2017 > cut off
PUBLICATIONS
International Clinical Trials

Cut off

A year ago in France, hardly anybody had heard of Emanuel
Macron, who has easily defeated the National Front’s Marine
Le Pen in the recent presidential election, and, at the time
of writing, looks to have founded a party that will win an
overwhelming majority in the French Parliament. Two months
ago, the UK’s Prime Minister, Theresa May, looked to be on
course for an equally overwhelming majority in the UK general
election, but is now hanging onto her position by the skin of
her teeth. These two rather contrasting outcomes have thrown
the UK’s Brexit strategy into sharp focus.

One of the major issues in the UK election was healthcare
and the concept of ‘our’ NHS. The UK spends, per capita,
significantly less on healthcare than many EU member states.
As a proportion of GDP, it will fall to 6.6%, compared to 7.3%
in 2014/15, whereas the EU average is 1.7% higher at 9.0%.
The government’s expenditure on R&D in the sector equally
falls below the average for the group of eight countries and is
at the bottom of the list.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Dr Graham Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement